Table 2 Estimated mean costs and health outcomes averted by RSV interventions (in thousands)
RSV-associated (‘000) mean [95% credible interval] | No intervention | mAb (6 months protection) | Maternal vaccine (5 months protection) | |
|---|---|---|---|---|
Under 1 year | 1–4 years | Under 1 year | Under 1 year | |
RSV cases (non-hospital + hospital cases) | 7649 [5366–10,138] | 13,192 [10,691–15,486] | 5928 [4363–7503] | 6464 [4712–8231] |
Hospital admissions | 668 [142–1853] | 1150 [258–3139] | 517 [112–1421] | 564 [122–1555] |
Deaths | 18 [3–55] | 22 [4–68] | 13 [2–40] | 15 [3–44] |
Discounted YLDs | 16 [10–24] | 26 [19–36] | 12 [8–18] | 13 [9–19] |
Discounted YLLs | 517 [89–1561] | 593 [103–1832] | 383 [68–1139] | 421 [74–1257] |
Discounted DALYs | 532 [102–1581] | 619 [124–1865] | 395 [77–1155] | 434 [85–1276] |
Intervention costs (including delivery) | NA | NA | 430,531 [430,531–430,531] | 220,775 [220,775–220,775] |
Discounted outpatient costs | 157,114 [69,436–341,707] | 256,189 [121,141–545,592] | 122,214 [55,209–264,714] | 133,078 [59,878–288,301] |
Discounted hospital costs | 75,254 [15,043–213,053] | 122,362 [25,518–343,347] | 58,975 [12,080–166,009] | 64,033 [13,123–179,855] |
Discounted total costs | 232,368 [112,538–443,860] | 378,551 [194,696–696,863] | 611,720 [521,121–770,475] | 417,885 [319,308–592,027] |
Burden averted | ||||
RSV cases averted | NA | NA | 1721 [979–2659] | 1186 [641–1924] |
Hospital admissions averted | NA | NA | 151 [29–443] | 104 [19–309] |
Deaths averted | NA | NA | 5 [1–15] | 3 [1–11] |
Discounted DALYs averted | NA | NA | 137 [23–423] | 98 [16–308] |
Net discounted costs | NA | NA | 379,352 [322,875–408,824] | 185,517 [144,452–206,446] |